Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Background: Retrospective studies suggest that change in ctDNA levels after 1-2 cycles of induction therapy in patients (pts) with previously untreated DLBCL is associated with event-free survival and overall survival (OS), using a log-fold change (LFC) cutoff in ctDNA levels of 2.0 (Kurtz DM, et al. J Clin Oncol 2018). The prognostic value of ctDNA has not been prospectively validated; this is a prespecified exploratory analysis of the prognostic value of ctDNA in the POLARIX study (NCT03274492). Methods: Pts in POLARIX had previously untreated DLBCL and were randomized to receive Pola-R-CHP or R-CHOP (Tilly H, et al. N Engl J Med 2022). Plasma ctDNA levels were measured at baseline and Cycle 2 Day 1 (C2D1) using the AVENIO NHL CAPP-Seq assay and are reported as mean mutant molecules per mL (MMPM; Herrera AF, et al. Blood Adv 2022). Plasma-depleted whole blood at baseline was used as a source of germline DNA to filter non-tumor-specific variants. Change in ctDNA levels was characterized as the log10 ratio between baseline and C2D1 MMPM (LFC); a LFC cutoff of 2.0 was used in this analysis. ctDNA clearance was determined with a detection cutoff of p=0.005 (Scherer F, et al. Sci Transl Med 2016). Univariate and multivariate Cox regression were used to identify relationships between ctDNA and progression-free survival (PFS) and OS. Hazard ratios (HR) are reported with 95% confidence intervals. Results: Results for paired ctDNA samples at baseline and C2D1 were available for 319/440 (72.5%; Pola-R-CHP) and 299/439 (68.1%; R-CHOP) pts. A median 135 (range: 1-644) variants were detected per pt. Baseline ctDNA levels were not statistically different between the two arms (median MMPM: Pola-R-CHP, 356; R-CHOP, 237; p=0.2); high baseline MMPM was associated with high baseline IPI score (p<0.001), ABC DLBCL (p<0.001), ECOG performance status >1 (p<0.001), and presence of bulky disease (>7.5cm; p<0.001). In both arms, pts with baseline ctDNA levels above the median MMPM had shorter PFS (Pola-R-CHP: HR, 1.96 [1.21-3.18]; R-CHOP: HR, 1.43 [0.92-2.20]) and OS (Pola-R-CHP: HR, 2.17 [1.07-4.37]; R-CHOP: HR, 2.10 [1.05-4.21]) than pts with baseline ctDNA levels below the median MMPM. Change in ctDNA levels from baseline to C2 as a continuous fold-change value was associated with PFS (HR, 0.75 [0.65-0.87]) and OS (HR, 0.78 [0.63-0.96]) in both arms. Pts with greater reductions in ctDNA levels after one treatment cycle had longer PFS and OS than pts with lower ctDNA reductions after one cycle. LFC ≥2.0 or undetectable ctDNA at C2D1 were achieved by 66.8% (213/319) of Pola-R-CHP-treated pts and 65.6% (196/299) of R-CHOP-treated pts. Stratifying pts at this LFC threshold was strongly prognostic of survival outcomes by arm (LFC <2.0 vs LFC ≥2.0, PFS HR: Pola-R-CHP 1.86 [1.18-2.92], R-CHOP 2.21 [1.43-3.41], OS HR: Pola-R-CHP 1.48 [0.77-2.81], R-CHOP 2.67 [1.34-5.30]). To define an optimal risk cutoff for pts receiving Pola-R-CHP, pts were grouped into training and validation cohorts. A LFC threshold of 2.5 (LFC ≥2.5 Pola-R-CHP: 54.2% [173/319]; R-CHOP: 54.8% [164/299]) was better able to identify pts at risk of poorer outcomes (LFC <2.5 vs LFC ≥2.5, PFS HR 2.89 [1.78-4.69], 24-month estimates 65.7% [58.3-74.0] vs 87.0% [82.0-92.2]; OS HR 1.87 [0.98-3.58], 24-month estimates 86.2% [80.8-92.0] vs 91.8% [87.7-96.0]; Figure A). In the Pola-R-CHP arm, pts with ctDNA clearance at C2D1 had superior outcomes vs pts with detectable ctDNA at C2D1 (not cleared vs cleared, PFS HR 2.98 [1.53-5.80]; OS HR 2.74 [1.07-7.02]). LFC 2.5 and ctDNA clearance were evaluated in separate multivariate analyses; it was found that both LFC 2.5 and ctDNA clearance are prognostic for PFS and OS in Pola-R-CHP treated pts, independent of key baseline risk factors (Figure B). LFC 2.5 and ctDNA clearance were also prognostic in R-CHOP-treated pts. Lastly, the top five commonly mutated genes identified in baseline ctDNA were HIST1H variants, TP53, PIM1, MYD88, and BCL2; analysis of clonal change on- and post-treatment is ongoing. Conclusions: Based on this prespecified exploratory analysis from the POLARIX study, ctDNA analysis has prognostic value for pts with previously untreated DLBCL. Pts who did not achieve ≥2.5 LFC and/or did not have ctDNA clearance following one cycle of Pola-R-CHP had inferior outcomes than those who did. Early changes in ctDNA levels may be of use in risk-adapted trial designs to identify pts in need of alternative treatment. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.